Get the Stockscreener App
3.71
0.27%
0.010
Liminatus Pharma Inc stock is traded at $3.71, with a volume of 23,220.
It is up +0.27% in the last 24 hours and down -37.23% over the past month.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
See More
Previous Close:
$3.70
Open:
$3.7
24h Volume:
23,220
Relative Volume:
0.03
Market Cap:
$4.98M
Revenue:
-
Net Income/Loss:
$-11.00M
P/E Ratio:
-9.3782
EPS:
-0.3956
Net Cash Flow:
$-11.99M
1W Performance:
-12.29%
1M Performance:
-37.23%
6M Performance:
-69.96%
1Y Performance:
-97.38%
1-Day Range:
$3.65
$3.82
1-Week Range:
$3.42
$4.26
52-Week Range:
$3.42
$145.00
Liminatus Pharma Inc Stock (LIMN) Company Profile
Name
Liminatus Pharma Inc
Sector
Industry
Phone
213-273-5453
Address
12611 HIDDENCREEK WAY, CERRITOS
Compare LIMN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIMN
Liminatus Pharma Inc
|
3.71 | 151.25K | 0 | -11.00M | -11.99M | -0.3956 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Liminatus Pharma Inc Stock (LIMN) Latest News
Press Releases about Liminatus Pharma, Inc.Class A Common Stock (Nasdaq:LIMN) - FinancialContent
17,272,739 Common Stock of Liminatus Pharma, Inc. are subject to a Lock-Up Agreement Ending on 19-AUG-2026. - marketscreener.com
Liminatus Pharma to implement 1-for-50 reverse stock split - Investing.com
Liminatus Pharma Enacts Reverse Split to Maintain Listing - TipRanks
Liminatus Pharma announces 1-for-50 reverse stock split - TipRanks
Liminatus Pharma Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Liminatus Pharma to implement 1-for-50 reverse stock split By Investing.com - Investing.com UK
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock - The Manila Times
Liminatus Pharma, Inc. Announces Reverse Stock Split of Its Common Stock - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Liminatus Pharma (LIMN) Stock Analysis Report | Financials & Insights - Benzinga France
Liminatus Pharma Warrants (LIMNW) Tumble 13.79% to $0.05 as Key Level Comes Into FocusScalping Stock Signals - vinanet.vn
Liminatus Pharma (LIMN) Slides 6.6% to $0.14, Testing Critical $0.13 SupportLow Vol ETF - vinanet.vn
Liminatus Pharma, Inc. Q2 2026: Net income $(1.41)M, EPS $(0.03) — 10-Q Summary - TradingView
Liminatus Pharma (LIMN) logs $2.5M loss and fights Nasdaq listing threats - Stock Titan
Liminatus Pharma (LIMN) Stock Jumps Over 50% on a Listing Update - TipRanks
These stocks are the most active in today's session - ChartMill
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Liminatus Pharma moves to Nasdaq Capital Market By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Liminatus Pharma moves to Nasdaq Capital Market - Investing.com
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement - The Manila Times
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Bid Price Compliance - Quiver Quantitative
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance ... - Herald and News
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance With Minimum Bid Price Requirement - Moomoo
Liminatus Pharma moves Nasdaq listing to Capital Market tier - Bitget
$Liminatus Pharma (LIMN.US)$ - moomoo.com
Liminatus Pharma Warrants (LIMNW) Jump 34% to $0.07 as Traders Eye Key Inflection PointMonthly Profile - dars.gov.et
Liminatus Pharma Warrants (LIMNW) Hold Flat at $0.07 as Narrow Range Defines TradingPrice Target - dars.gov.et
Liminatus Pharma Shareholders Approve Reverse Stock Split Plan - The Globe and Mail
Liminatus Pharma Warrants (LIMNW) Remain Flat at $0.06 as Key Levels ConvergeCalendar Spread Trade - dars.gov.et
Liminatus Pharma, Inc. Primary Exchange Listing has Changed to Nasdaq Capital Market from Nasdaq Global Market - marketscreener.com
Liminatus Pharma, Inc. Revenue Breakdown – NASDAQ:LIMN - TradingView
Liminatus Pharma Warrants (LIMNW) Hold Steady at $0.04 – Flat Trading Signals ConsolidationBackspread Trade - vinanet.vn
Liminatus Pharma Inc. (LIMN) Edges Higher as Stock Tests Key Resistance LevelETF Creation Redemption - dars.gov.et
LIMN|Liminatus Pharma Ord Shs Class A|Price:0.119|Chg%:+0.002 - TradingKey
Liminatus Pharma, Inc. Revenue Breakdown – NASDAQ:LIMNW - TradingView
Liminatus Pharma Faces Nasdaq Delisting Risk, Plans Reverse Split - The Globe and Mail
Liminatus Pharma, Inc. Revenue Breakdown – BOATS:LIMN - TradingView
Liminatus Pharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Liminatus Pharma, Inc. Class A Common Stock (NASDAQ: LIMN) Stock Price, News & Analysis - Kalkine
Samda Biolab discloses 5.1% Liminatus Pharma (LIMN) ownership position - Stock Titan
Frontier tech research, news & data - MLQ.ai
Liminatus Pharma Warrants (LIMNW) Edge Higher: A Closer Look at the $0.06 LevelEarnings Breakout Stocks - dars.gov.et
Enterprise value to EBITDA forward of Liminatus Pharma, Inc. – BOATS:LIMNW - TradingView
Liminatus Pharma (LIMN) Plunges 16.72% as Key Support Nears $0.11PCR Mean Reversion - vinanet.vn
Price to earnings forward of Liminatus Pharma, Inc. – BOATS:LIMNW - TradingView
Enterprise value to EBIT forward of Liminatus Pharma, Inc. – BOATS:LIMNW - TradingView
Liminatus Pharma (LIMN) - Moomoo
Liminatus Pharma Warrants Plunge 36%: Key Levels and Outlook for LIMNWZero Lag EMA - vinanet.vn
Curious about the most active stocks on Thursday? - ChartMill
Liminatus Pharma Inc Stock (LIMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):